
Ocean Biomedical CEO Elizabeth Ng (L) and Aesther CEO Suren Ajjarapu
After ditching electric vehicle parts maker, a SPAC chooses a Brown spinout that had tested the IPO waters
While the market remains difficult to navigate, the latest SPAC merger shows that biotechs and blank checks are still willing to brace the choppy waters — and for both parties involved in the latest deal, it’s not their first attempt at a successful voyage onto Wall Street.
Ocean Biomedical wanted to go the IPO route but that didn’t pan out.
Aesther Healthcare Acquisition, the biotech’s SPAC partner that was disclosed Wednesday, originally wanted to merge with a gear maker for electric vehicles but that May plan went bust in July.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters